The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R01 Clinical Trial Optional) | RFA HL 24 008

Opportunity Information: Apply for RFA HL 24 008

The NIH funding opportunity RFA-HL-24-008, titled "The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R01 Clinical Trial Optional)," is focused on clarifying how insufficient sleep and circadian rhythm disruption influence the biology of Type 1 Diabetes (T1D), especially in ways that shape glycemic control and cardiovascular risk. The central aim is not simply to document that sleep problems occur in T1D, but to dig into clinically meaningful mechanisms that explain how sleep and circadian factors drive metabolic and cardiovascular changes, affect disease progression over time, and potentially alter how patients respond to treatment. The broader payoff NIH is looking for is evidence that can support practical sleep- or circadian-based strategies that ultimately improve outcomes for people living with T1D and reduce related cardiovascular complications.

This R01 emphasizes mechanism-focused, clinically relevant research at the intersection of sleep/circadian science, diabetes, and cardiovascular biology. Applications are expected to bring together multidisciplinary expertise, for example by integrating sleep and circadian measurement and biology with endocrinology/diabetes management and cardiovascular phenotyping. The opportunity is designed to support work that gets closer to explaining "how and why" sleep deficiency and circadian disruption matter in T1D, rather than only showing "whether" they are associated with outcomes. Because the notice is labeled "Clinical Trial Optional," applicants may propose studies that include a clinical trial component if it is scientifically justified, but a clinical trial is not required. The key is that any human research should be tightly connected to mechanistic questions with clear relevance to improving treatment and lowering cardiovascular risk in T1D.

The NOFO also draws clear boundaries around what it will not fund under this announcement. Studies that are purely observational, general epidemiology projects, and efficacy trials focused mainly on testing whether an intervention works (without a strong mechanistic emphasis) are described as non-responsive. Basic animal research is also non-responsive for this particular solicitation. In practice, that means proposals should avoid being framed as population-level association studies, standard cohort analyses, or standalone randomized trials that primarily measure clinical endpoints without explaining underlying pathways. Instead, applicants should focus on mechanistic human research that can link sleep and circadian disruption to measurable metabolic and cardiovascular pathobiology, disease trajectory, and treatment response in T1D.

Eligibility is broad and includes many standard NIH-eligible applicant types such as state, county, and local governments; public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (other than small businesses) and small businesses; independent school districts; special district governments; public housing authorities; and federally recognized tribal governments and other tribal organizations. The announcement explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIS institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. Foreign institutions (non-U.S. entities) are not eligible to apply as the applicant organization, but non-U.S. components of U.S. organizations are allowed, and foreign components (as NIH defines them) may be included when permitted under NIH policy.

From an administrative standpoint, this is a discretionary grant using the NIH R01 mechanism, with activity in the health domain and CFDA numbers listed as 93.233, 93.837, and 93.838. The original closing date in the provided source data is 2023-10-11, and the listed award ceiling is $420,000 (as provided in the dataset). Overall, the solicitation is best suited for teams proposing hypothesis-driven, mechanistic human studies that directly connect sleep and circadian disruption to the metabolic and cardiovascular complications that shape real-world outcomes in Type 1 Diabetes, with an eye toward actionable pathways that could later support targeted sleep or circadian interventions.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.837, 93.838.
• This funding opportunity was created on 2023-07-20.
• Applicants must submit their applications by 2023-10-11. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $420,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA HL 24 008

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: